Alemtuzumab
| Use attributes for filter ! | |
| Formula | C6468H10066N1732O2005S40 |
|---|---|
| Trade name | Campath, MabCampath, Lemtrada, others |
| Target | CD52 |
| License data | EMA |
| Elimination half-life | ~288 hrs |
| ATC code | L04AA34 (WHO) |
| Music groups | Natalizumab |
| Ocrelizumab | |
| Teriflunomide | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951280 |
About Alemtuzumab
Alemtuzumab is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. In CLL has been used as both a first line and second line treatment. In MS it is generally only recommended if other treatments have not worked. It is given by injection into a vein.